Abstract
CSPC PHARMA will report Q2 2026 results on October 20, 2026 post-Market; this preview outlines consensus revenue and profit expectations, last quarter’s actuals, and key drivers to watch across innovative drugs, bulk products, and operating margins.
Market Forecast
For the current quarter, the company-level forecast indicates revenue of 9.65 billion RMB with a year-over-year increase of 25.43%, EBIT of 4.19 billion RMB with a year-over-year increase of 113.41%, and EPS of 0.256 with a year-over-year increase of 92.71%. The forecast implies continued margin recovery, with EBIT leverage suggesting improved product mix and cost control, and EPS expansion on higher scale; YoY figures follow the decimal-to-percentage conversion rule. The main business is expected to be led by finished drugs, with growth supported by new launches and broader demand; the highest-potential segment appears to be innovative finished drugs, expected to accelerate revenue and mix improvement.
Last Quarter Review
Last quarter, the company recorded revenue of 6.47 billion RMB, a 7.83% year-over-year decline, gross profit margin of 66.02%, net profit attributable to the parent of 860.00 million RMB with quarter-on-quarter growth of 131.92%, net profit margin of 13.30%, and adjusted EPS of 0.073 with a year-over-year decline of 43.41%. A notable highlight was sequential profit rebound as mix improved and costs normalized, driving significant quarter-on-quarter net income recovery. By segment, finished drugs contributed 5.22 billion RMB, Bulk Products – Vitamin C 0.50 billion RMB, Bulk Products – Antibiotics 0.34 billion RMB, and Functional Food and Others 0.47 billion RMB, indicating finished drugs as the core revenue engine.
Current Quarter Outlook
Main business: Finished drugs and their margin trajectory
Finished drugs remain the revenue anchor, contributing over 80% last quarter and setting the base for scale effects this quarter. The forecasted revenue growth of 25.43% YoY and EBIT growth of 113.41% YoY, together with the prior quarter’s gross margin of 66.02%, point to operating leverage as volumes recover and the product mix tilts toward higher-value therapies. Execution in hospital channels and continued breadth of indications should help sustain gross margin stability near the prior-quarter level, while cost discipline supports EPS uplift. A key watchpoint is price-volume trade-offs from centralized procurement; however, the projected EBIT ramp suggests mix improvement offsetting pricing headwinds.
Most promising business: Innovative finished drugs
Within finished drugs, innovative therapeutics appear positioned for faster-than-average growth as pipeline conversions and new indications broaden the addressable market. The margin profile of innovative molecules typically exceeds that of generics and bulk APIs, aligning with the forecasted EPS expansion of 92.71% YoY. Revenue contribution from this sub-segment is expected to rise within the overall 9.65 billion RMB estimate, aiding blended gross margin resilience and supporting the 4.19 billion RMB EBIT outlook. Monitoring uptake trends for recent launches and formulary inclusions will be critical to validating sustained double-digit growth.
Key stock price drivers this quarter
Earnings sensitivity is likely to center on the scale and mix of finished drugs, the stability of API pricing cycles in bulk products, and operating expense efficiency. If the realized gross margin holds near the last quarter’s 66.02% while revenue tracks the 9.65 billion RMB forecast, incremental EBIT could surprise to the upside relative to modeled expectations. Conversely, any accelerated pricing pressure in hospital tenders or slower-than-expected uptake of new therapies could compress margins and temper EPS progress. Investors will also pay close attention to working capital dynamics and cash conversion as volume scales.
Analyst Opinions
Most institutional commentary skews constructive on the quarter’s setup, with the majority expecting a revenue reacceleration and margin recovery to continue on the back of finished-drug strength and improving mix. Several analysts highlight the scale-driven operating leverage implied by the forecasted 113.41% YoY EBIT growth and nearly doubling of EPS, citing favorable product launches as well as disciplined cost control. The prevailing view is bullish, emphasizing that finished drugs and innovative therapies can offset pricing headwinds in bulk categories and centralized procurement impacts, while the near-term catalyst remains confirmation of top-line growth near 9.65 billion RMB and resilient gross margins.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments